Citations

Mayo Clinic

Showing 10 of 108403 citations.

LEDGF Dominant Interference Proteins Demonstrate Prenuclear Exposure of HIV-1 Integrase and Synergize with LEDGF Depletion To Destroy Viral Infectivity
Meehan, Anne M. , Saenz, Dyana T. , Morrison, James H. , Hu, Chunling , Peretz, Mary, Poeschla, Eric M. , Hu, Chunling

Journal of Virology | January 27, 2011 | Volume: 85 | Issue: 7 | Pages: 3570-3583

10.1128/jvi.01295-10 | PMID 21270171 Get It

ABSTRACT Target cell overexpression of the integrase binding domain (IBD) of LEDGF/p75 (LEDGF) inhibits HIV-1 replication. The mechanism and protein structure requirements for this dominant interference are unclear. More generally, how and when HIV-1 uncoating occurs postentry is poorly defined, and it is unknown whether integrase within the evolving viral core becomes accessible to cellular proteins prior to nuclear entry. We used LEDGF dominant interference to address the latter question while characterizing determinants of IBD antiviral activity. Fusions of green fluorescent protein (GFP) with multiple C-terminal segments of LEDGF inhibited HIV-1 replication substantially, but minimal chimeras of either polarity (GFP-IBD or IBD-GFP) were most effective. Combining GFP-IBD expression with LEDGF depletion was profoundly antiviral. CD4 + T cell lines were rendered virtually uninfectable, with single-cycle HIV-1 infectivity reduced 4 logs and high-input (multiplicity of infection = 5.0) replication completely blocked. We restricted GFP-IBD to specific intracellular locations and found that antiviral activity was preserved when the protein was confined to the cytoplasm or directed to the nuclear envelope. The life cycle block triggered by the cytoplasm-restricted protein manifested after nuclear entry, at the level of integration. We conclude that integrase within the viral core becomes accessible to host cell protein interaction in the cytoplasm. LEDGF dominant interference and depletion impair HIV-1 integration at distinct postentry stages. GFP-IBD may trigger premature or improper integrase oligomerization.
Can we help patients with chronic migraine?
Mack, Kenneth J.

Neurology | January 27, 2011 | Volume: 76 | Issue: 8 | Pages: 682-683

10.1212/wnl.0b013e31820d6315 | PMID 21270416 Get It

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
Wang, Eunice S. , Baer, Maria R. , Perl, Alexander E. , Coutré, Steven , Stuart, Robert K. , Baccarani, Michele , Cripe, Larry D., Tallman, Martin S. , Meloni, Giovanna, Godley, Lucy A. , Langston, Amelia , Amadori, Sergio , Lewis, Ian D., Nagler, Arnon , Stone, Richard M. , Yee, Karen , Douer, Dan , Wiktor-Jędrzejczak, W , Juliusson, Gunnar , Litzow, Mark R. , Petersdorf, Stephen H., Sanz, Miguel Á. , Kantarjian, Hagop M. , Tremmel, Lothar, Bensen-Kennedy, Debra M., Small, Donald , Levis, Mark J. , Ravandi, Farhad , Wang, Eunice S. , Erba, Harry Paul , Advani, Anjali S. , Sato, Takashi , Smith, B. Douglas , Godley, Lucy A , Kantarjian, Hagop

Blood | January 26, 2011 | Volume: 117 | Issue: 12 | Pages: 3294-3301

10.1182/blood-2010-08-301796 | PMID 21270442 Get It

Abstract In a randomized trial of therapy for FMS-like tyrosine kinase-3 (FLT3) mutant acute myeloid leukemia in first relapse, 224 patients received chemotherapy alone or followed by 80 mg of the FLT3 inhibitor lestaurtinib twice daily. Endpoints included complete remission or complete remission with incomplete platelet recovery (CR/CRp), overall survival, safety, and tolerability. Correlative studies included pharmacokinetics and analysis of in vivo FLT3 inhibition. There were 29 patients with CR/CRp in the lestaurtinib arm and 23 in the control arm (26% vs 21%; P = .35), and no difference in overall survival between the 2 arms. There was evidence of toxicity in the lestaurtinib-treated patients, particularly those with plasma levels in excess of 20μM. In the lestaurtinib arm, FLT3 inhibition was highly correlated with remission rate, but target inhibition on day 15 was achieved in only 58% of patients receiving lestaurtinib. Given that such a small proportion of patients on this trial achieved sustained FLT3 inhibition in vivo, any conclusions regarding the efficacy of combining FLT3 inhibition with chemotherapy are limited. Overall, lestaurtinib treatment after chemotherapy did not increase response rates or prolong survival of patients with FLT3 mutant acute myeloid leukemia in first relapse. This study is registered at www.clinicaltrials.gov as #NCT00079482.
Performance and Cost Analysis of Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry for Routine Identification of Yeast
Dhiman, Neelam , Hall, Leslie, Wohlfiel, Sherri L., Buckwalter, Seanne P., Wengenack, Nancy L.

Journal of Clinical Microbiology | January 26, 2011 | Volume: 49 | Issue: 4 | Pages: 1614-1616

10.1128/jcm.02381-10 | PMID 21270234 Get It

ABSTRACT Matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) mass spectrometry was compared to phenotypic testing for yeast identification. MALDI-TOF mass spectrometry yielded 96.3% and 84.5% accurate species level identifications (spectral scores, ≥1.8) for 138 common and 103 archived strains of yeast. MALDI-TOF mass spectrometry is accurate, rapid (5.1 min of hands-on time/identification), and cost-effective ($0.50/sample) for yeast identification in the clinical laboratory.
HSulf-1 Modulates FGF2- and Hypoxia-Mediated Migration and Invasion of Breast Cancer Cells
Khurana, Ashwani, Liu, Peng , Mellone, Pasquale, Vincenzi, Bruno , Datta, Kaustubh , Yang, Bo , Lingle, Wilma L., Chien, Jeremy , Baldi, Alfonso , Shridhar, Viji , Lorenzon, Laura , Linhardt, Robert J. , Chien, Jeremey , Vincenzi, Bruno

Cancer Research | January 25, 2011 | Volume: 71 | Issue: 6 | Pages: 2152-2161

10.1158/0008-5472.can-10-3059 | PMID 21266348 Get It

Abstract HSulf-1 modulates the sulfation states of heparan sulfate proteoglycans critical for heparin binding growth factor signaling. In the present study, we show that HSulf-1 is transcriptionally deregulated under hypoxia in breast cancer cell lines. Knockdown of HIF-1α rescued HSulf-1 downregulation imposed by hypoxia, both at the RNA and protein levels. Chromatin immunoprecipitation with HIF-1α and HIF-2α antibodies confirmed recruitment of HIF-α proteins to the two functional hypoxia-responsive elements on the native HSulf-1 promoter. HSulf-1 depletion in breast cancer cells resulted in an increased and sustained bFGF2 (basic fibroblast growth factor) signaling and promoted cell migration and invasion under hypoxic conditions. In addition, FGFR2 (fibroblast growth factor receptor 2) depletion in HSulf-1–silenced breast cancer cells attenuated hypoxia-mediated cell invasion. Immunohistochemical analysis of 53 invasive ductal carcinomas and their autologous metastatic lesions revealed an inverse correlation for the expression of HSulf-1 to CAIX in both the primary tumors (P ≥ 0.0198) and metastatic lesions (P ≥ 0.0067), respectively, by χ2 test. Finally, HSulf-1 expression levels in breast tumors by RNA in situ hybridization showed that high HSulf-1 expression is associated with increased disease-free and overall survival (P ≥ 0.03 and P ≥ 0.0001, respectively). Collectively, these results reveal an important link between loss of HSulf-1 under hypoxic microenvironment and increased growth factor signaling, cell migration, and invasion. Cancer Res; 71(6); 2152–61. ©2011 AACR.
Impact of Aging on Conduit Artery Retrograde and Oscillatory Shear at Rest and During Exercise
Padilla, Jaume , Simmons, Grant H., Laughlin, M. Harold, Joyner, Michael J. , Casey, Darren P. , Fadel, Paul J. , Padilla, Jaume , Joyner, Michael J

Hypertension | January 25, 2011 | Volume: 57 | Issue: 3 | Pages: 484-489

10.1161/hypertensionaha.110.165365 | PMID 21263118 Get It

Aging has been recently associated with increased retrograde and oscillatory shear in peripheral conduit arteries, a hemodynamic environment that favors a proatherogenic endothelial cell phenotype. We evaluated whether nitric oxide (NO) bioavailability in resistance vessels contributes to age-related differences in shear rate patterns in upstream conduit arteries at rest and during rhythmic muscle contraction. Younger (n=11, age 26±2 years) and older (n=11, age 61±2 years) healthy subjects received intra-arterial saline (control) and the NO synthase inhibitor N G -Monomethyl- l -arginine. Brachial artery diameter and velocities were measured via Doppler ultrasound at rest and during a 5-minute bout of rhythmic forearm exercise. At rest, older subjects exhibited greater brachial artery retrograde and oscillatory shear (−13.2±3.0 s −1 and 0.11±.0.02 arbitrary units, respectively) compared with young subjects (−4.8±2.3 s −1 and 0.04±0.02 arbitrary units, respectively; both P <0.05). NO synthase inhibition in the forearm circulation of young, but not of older, subjects increased retrograde and oscillatory shear (both P <0.05), such that differences between young and old at rest were abolished (both P >0.05). From rest to steady-state exercise, older subjects decreased retrograde and oscillatory shear (both P <0.05) to the extent that no exercise-related differences were found between groups (both P >0.05). Inhibition of NO synthase in the forearm circulation did not affect retrograde and oscillatory shear during exercise in either group (all P >0.05). These data demonstrate for the first time that reduced NO bioavailability in the resistance vessels contributes, in part, to age-related discrepancies in resting shear patterns, thus identifying a potential mechanism for increased risk of atherosclerotic disease in conduit arteries.
Measurements of Plasma Methoxytyramine, Normetanephrine, and Metanephrine as Discriminators of Different Hereditary Forms of Pheochromocytoma
Eisenhofer, Graeme , Lenders, Jacques W.M. , Timmers, Henri , Mannelli, Massimo , Grebe, Stefan K., Hofbauer, Lorenz C. , Bornstein, Stefan R. , Tiebel, Oliver , Adams, Karen T. , Pacák, Karel , Bratslavsky, Gennady , Linehan, William Marston , Hofbauer, Lorenz C

Clinical Chemistry | January 25, 2011 | Volume: 57 | Issue: 3 | Pages: 411-420

10.1373/clinchem.2010.153320 | PMID 21262951 Get It

BACKGROUND Pheochromocytomas are rare catecholamine-producing tumors derived in more than 30% of cases from mutations in 9 tumor-susceptibility genes identified to date, including von Hippel-Lindau tumor suppressor (VHL); succinate dehydrogenase complex, subunit B, iron sulfur (Ip) (SDHB); and succinate dehydrogenase complex, subunit D, integral membrane protein (SDHD). Testing of multiple genes is often undertaken at considerable expense before a mutation is detected. This study assessed whether measurements of plasma metanephrine, normetanephrine, and methoxytyramine, the O-methylated metabolites of catecholamines, might help to distinguish different hereditary forms of the tumor. METHODS Plasma concentrations of O-methylated metabolites were measured by liquid chromatography with electrochemical detection in 173 patients with pheochromocytoma, including 38 with multiple endocrine neoplasia type 2 (MEN 2), 10 with neurofibromatosis type 1 (NF1), 66 with von Hippel-Lindau (VHL) syndrome, and 59 with mutations of SDHB or SDHD. RESULTS In contrast to patients with VHL, SDHB, and SDHD mutations, all patients with MEN 2 and NF1 presented with tumors characterized by increased plasma concentrations of metanephrine (indicating epinephrine production). VHL patients usually showed solitary increases in normetanephrine (indicating norepinephrine production), whereas additional or solitary increases in methoxytyramine (indicating dopamine production) characterized 70% of patients with SDHB and SDHD mutations. Patients with NF1 and MEN 2 could be discriminated from those with VHL, SDHB, and SDHD gene mutations in 99% of cases by the combination of normetanephrine and metanephrine. Measurements of plasma methoxytyramine discriminated patients with SDHB and SDHD mutations from those with VHL mutations in an additional 78% of cases. CONCLUSIONS The distinct patterns of plasma catecholamine O-methylated metabolites in patients with hereditary pheochromocytoma provide an easily used tool to guide cost-effective genotyping of underlying disease-causing mutations.
Myasthenic syndrome caused by plectinopathy
Selcen, Duygu , Juel, Vern C. , Hobson‐Webb, Lisa D., Smith, Edward C. , Stickler, David E., Bite, Anna V., Ohno, Kinji , Engel, Andrew G.

Neurology | January 24, 2011 | Volume: 76 | Issue: 4 | Pages: 327-336

10.1212/wnl.0b013e31820882bd | PMID 21263134 Get It

Accuracy of family history information on epilepsy and other seizure disorders
Ottman, Ruth , Barker‐Cummings, Christie, Leibson, C.L., Vasoli, Vincent M. , Hauser, W. Allen , Buchhalter, J

Neurology | January 24, 2011 | Volume: 76 | Issue: 4 | Pages: 390-396

10.1212/wnl.0b013e3182088286 | PMID 21263140 Get It

Bro1 binding to Snf7 regulates ESCRT-III membrane scission activity in yeast
Wemmer, Megan, Azmi, Ishara F. , Davies, Brian A., Katzmann, David J. , Odorizzi, Greg , West, Matthew

Journal of Cell Biology | January 24, 2011 | Volume: 192 | Issue: 2 | Pages: 295-306

10.1083/jcb.201007018 | PMID 21263029 Get It

Endosomal sorting complexes required for transport (ESCRTs) promote the invagination of vesicles into the lumen of endosomes, the budding of enveloped viruses, and the separation of cells during cytokinesis. These processes share a topologically similar membrane scission event facilitated by ESCRT-III assembly at the cytosolic surface of the membrane. The Snf7 subunit of ESCRT-III in yeast binds directly to an auxiliary protein, Bro1. Like ESCRT-III, Bro1 is required for the formation of intralumenal vesicles at endosomes, but its role in membrane scission is unknown. We show that overexpression of Bro1 or its N-terminal Bro1 domain that binds Snf7 enhances the stability of ESCRT-III by inhibiting Vps4-mediated disassembly in vivo and in vitro. This stabilization effect correlates with a reduced frequency in the detachment of intralumenal vesicles as observed by electron tomography, implicating Bro1 as a regulator of ESCRT-III disassembly and membrane scission activity.